[HTML] sciencedirect.com

[HTML][HTML] Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

D Voci, A Götschi, U Held, R Bingisser, G Colucci… - Thrombosis research, 2023 - Elsevier
Introduction The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients
remain unclear. We present the 90-day results from the randomised, open-label, parallel …
被引用次数：14 相关文章
[PDF] unige.ch

[PDF][PDF] Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

D Voci, A Götschi, U Held, R Bingisser, G Colucci… - access.archive-ouverte.unige.ch
Introduction: The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients
remain unclear. We present the 90-day results from the randomised, open-label, parallel …

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.

D Voci, A Götschi, U Held, R Bingisser, G Colucci… - 2023 - cabidigitallibrary.org
Introduction: The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients
remain unclear. We present the 90-day results from the randomised, open-label, parallel …

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

D Voci, A Götschi, U Held, R Bingisser… - Thrombosis …, 2023 - thrombosisresearch.com
Introduction The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients
remain unclear. We present the 90-day results from the randomised, open-label, parallel …

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

D Voci, A Götschi, U Held, R Bingisser, G Colucci… - 2023 - pubmed.ncbi.nlm.nih.gov
Introduction The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients
remain unclear. We present the 90-day results from the randomised, open-label, parallel …

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.

D Voci, A Götschi, U Held, R Bingisser… - Thrombosis …, 2023 - boris.unibe.ch
INTRODUCTION The benefits of early thromboprophylaxis in symptomatic COVID-19
outpatients remain unclear. We present the 90-day results from the randomised, open-label …

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

D Voci, A Götschi, U Held, R Bingisser, G Colucci… - Thrombosis …, 2023 - zora.uzh.ch
INTRODUCTION The benefits of early thromboprophylaxis in symptomatic COVID-19
outpatients remain unclear. We present the 90-day results from the randomised, open-label …
[PDF] archive.org

[PDF][PDF] Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

D Voci, A Götschi, U Held, R Bingisser, G Colucci… - 2022 - scholar.archive.org
INTRODUCTION The benefits of early thromboprophylaxis in symptomatic COVID-19
outpatients remain unclear. We present the 90-day results from the randomised, open-label …

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.

D Voci, A Götschi, U Held, R Bingisser… - Thrombosis …, 2022 - europepmc.org
Methods Outpatients aged 50 years or older with acute symptomatic COVID-19 were
randomised to receive enoxaparin 40 mg for 14 days once daily vs. standard of care (no …
[HTML] nih.gov

[HTML][HTML] Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

D Voci, A Götschi, U Held, R Bingisser… - Thrombosis …, 2023 - ncbi.nlm.nih.gov
Methods Outpatients aged 50 years or older with acute symptomatic COVID-19 were
randomised to receive enoxaparin 40 mg for 14 days once daily vs. standard of care (no …